Featured

Mar 18 2021

Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application Covering Extracorporeal Treatment of COVID-19 and Other Medical Maladies

By Admin|2021-03-17T21:09:58-04:00March 18th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 18, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Method for Treating and Curing Covid-19 Infection.” The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously. William A. ...

Mar 16 2021

Halberd Corporation Starts VITA-SHIELD-MAX(TM) Immunity Boosting Nutraceutical Production

By Admin|2021-03-15T18:53:11-04:00March 16th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 16, 2021 – Halberd Corporation (OTC PINK:HALB) has contracted with a major nutraceutical manufacturer to produce its initial production lot of Halberd’s VITA-SHIELD-MAXTM Immune Booster. Halberd’s scientists designed this proprietary combination of vitamins and minerals to help the body increase its natural immunity and promote general health. Dr. Patricio Reyes, Halberd ...

Mar 11 2021

Halberd Corporation Files VITA-SHIELD-MAX(TM) Trademark For Immunity Boosting Nutraceutical

By Admin|2021-03-10T19:37:28-05:00March 11th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 11, 2021 – Halberd Corporation (OTC PINK:HALB) has filed for trademark protection for the name VITA-SHIELD-MAXTM for its proprietary blend of over-the-counter nutraceuticals designed to boost the body’s immunity and generally enhance health. William A. Hartman, Chairman, President & CEO of Halberd Corp., stated, “We are pleased to be able to ...

Mar 9 2021

Halberd Corporation’s CEO Interviewed on “The Stock Day Podcast” – Focus on Halberd’s New 20x Affinity Neutralizing SARS-COV-2 Antibody

By Admin|2021-03-08T20:35:16-05:00March 9th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 9, 2021 – Halberd Corporation’s (OTC PINK:HALB) Chairman, President & CEO, William A. Hartman, was interviewed recently on The Stock Day Podcast, hosted by Everett Jolly. In the interview, Mr. Hartman reviewed the company’s progress in developing SARS-CoV-2 spike protein antibodies and how they can be combined with other Halberd technologies ...

Mar 2 2021

Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater

By Admin|2021-03-01T20:05:18-05:00March 2nd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 2, 2021 – Halberd Corp. (OTC PINK:HALB) has recently produced a proprietary monoclonal antibody that has at least 20 times greater neutralizing affinity than their original antibody against the SARS-COV 2 Spike protein. Dr. Reyes, Halberd’s Chief Technical Officer, indicated, “Our latest results indicate increased specificity of our second antibody, which ...

Feb 16 2021

Halberd Collaborates With GreenBioAZ, Inc. For the Development of Its Patent Pending Radio Frequency Technology to Eliminate Disease Pathogens

By Admin|2021-02-15T21:23:39-05:00February 16th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, February 16, 2021 – Halberd Corp. (OTC PINK:HALB) has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease pathogens. The methodology entails treating bodily fluids with an Antibody-Metallic Moiety Conjugate (AMMC) which targets a specific pathogen such as SARS-CoV-2 during extracorporeally ...

Feb 1 2021

Halberd Corporation’s CEO Interviewed on The Stock Day Podcast and on MoneyTV

By Admin|2021-01-31T19:36:34-05:00February 1st, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, February 1, 2021 – Halberd Corporation’s (OTC PINK:HALB) Chairman, President & CEO, William A. Hartman, was interviewed recently on The Stock Day Podcast, hosted by Everett Jolly, and on MoneyTV, hosted by Don Baillargeon. In each interview, Mr. Hartman reviewed the company’s progress on developing SARS-CoV-2 spike protein antibodies which could be ...

Jan 28 2021

Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast

By Halberd|2021-01-28T08:45:25-05:00January 28th, 2021|Featured, Investor News, News|0 Comments

Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast Phoenix, AZ January 28th, 2021 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) ("the Company"), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, ...

Jan 14 2021

Halberd Corp. Develops Medication to Boost Immune System Against SARS-CoV-2 (Covid-19)

By Admin|2021-01-13T18:47:16-05:00January 14th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 14, 2021 – Halberd Corp. (OTC PINK: "HALB") announced the filing of a provisional patent application on a proprietary combination of nutritional supplements (melatonin, zinc and Vitamin D) combined with low dose Naltrexone designed to reduce the severity of Covid-19 symptoms. This proprietary combination of nutritional supplements is based on numerous ...

Jan 12 2021

Halberd Corporation’s Covid-19 Efforts Recognized in Wall Street PR News Article

By Admin|2021-01-11T19:57:47-05:00January 12th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 12, 2021 – Halberd Corp. (OTC PINK: "HALB") was recently included alongside Novavax Inc (NASDAQ:NVAX) and Moderna Inc (NASDAQ:MRNA) in a recent Wall Street PR article on Covid-19 related stocks poised to have an impact in 2021. Halberd was noted to be working in a different direction from the vaccine producers. ...